Neurobiology of Hearing Loss and Ear DiseaseView this Special Issue
Research Article | Open Access
Hyun Mi Ju, Sun Hee Lee, Jin Sil Choi, Young Joon Seo, "A Simple Model for Inducing Optimal Increase of SDF-1 with Aminoglycoside Ototoxicity", BioMed Research International, vol. 2017, Article ID 4630241, 9 pages, 2017. https://doi.org/10.1155/2017/4630241
A Simple Model for Inducing Optimal Increase of SDF-1 with Aminoglycoside Ototoxicity
Objectives. As a homing factor of stem cell, stromal derived factor-1 (SDF-1) is important for the regenerative research in ototoxicity. Mice models with aminoglycoside ototoxicity have been widely used to study the regeneration capacity of MSCs in repair of cochlear injury. We developed a mouse model with maximal increase in SDF-1 levels in the inner ear, according to the “one-shot” doses of kanamycin and furosemide. Methods. C57BL/6 mice had kanamycin (420, 550, and 600 mg/kg) dissolved in PBS, followed by an intraperitoneal injection of furosemide (130 mg/kg). The injuries of inner ear were measured with hearing thresholds, histology, and outer hair cell counts at 0, 3, 5, 7, 10, and 14 days before the sacrifice. The levels of SDF-1 in the inner ear were tested by real-time RT-PCR and immunohistochemistry. Results. There were a significant reduction in hearing thresholds and a maximal increase of SDF-1 levels in the furosemide 130 mg/kg + kanamycin 550 mg/kg group, but severe hearing deterioration over time was observed in the furosemide 130 mg/kg + kanamycin 600 mg/kg group and four mice were dead. SDF-1 was detected mostly in the stria vascularis and organ of Corti showing the highest increase in expression. Conclusion. We observed optimal induction of the stem cell homing factor in the newly generated aminoglycoside-induced ototoxicity mouse model using a “one-shot” protocol. This study regarding high SDF-1 levels in our mouse model of ototoxicity would play a major role in the development of therapeutic agents using MSC homing.
Stromal derived factor-1 (SDF-1) is a cytokine for stimulating the homing of stem cells into injured organs. The expression of SDF-1 in injured tissue correlates with recruitment of stem cells and tissue regeneration. Recent studies have shown that homing of mesenchymal stem cells (MSCs) across the blood-brain barrier (BBB) occurred in ischemic brain tissue. Myocardial protection by homing of stem cells was also shown in myocardial infarction via mobilization of the stem cells into the injured myocardial tissue and increase in local angiogenesis after myocardial infarction.
Mice models with aminoglycoside ototoxicity have been widely used to study the regeneration capacity of MSCs in repair of cochlear injury. Several studies showed that mice can be used as models for aminoglycoside-induced hearing loss using a “one-shot” protocol, in which a single dose of kanamycin is accompanied by a dose of the loop diuretic furosemide [1, 2].
In the case of cochlear homing, Tan et al.  demonstrated that upregulation of SDF-1 in the spiral ligament after acoustic deafening could promote the homing capability of bone marrow-derived cells to an injured cochlea. Another study showed that efficient invasion of MSCs to the inner tissue occurred when MSCs, which had enhanced expression of the SDF-1 receptor and the C-X-C chemokine receptor type 4 (CXCR4), were transplanted in the lateral semicircular canal .
In the field of ear research, researches are being actively carried out to bring about the regeneration of hair cells using stem cell homing . To prove that this ototoxicity mice model, in which SDF-1 is markedly increased, could be the appropriate model to study homing, we confirmed the changes in SDF-1 levels with increasing hearing thresholds based on the various conditions of one-shot ototoxicity. Thereafter, we demonstrated an effective homing phenomenon in a mouse model with maximal increase in SDF-1 levels in the inner ear.
87 male C57BL/6 mice, including 24 mice for the changes of hearing thresholds after the ototoxicity drugs, were allowed free access to water and regular mouse diet and were kept at room temperature under a standard 12 h light/dark cycle for 1 week of acclimatization before the experiments. The animals were 5 weeks old and weighed approximately 18–25 g. The mice were anaesthetized by intraperitoneal injection of 30 mg/kg tiletamine-zolazepam (Zoletil, 500 mg/vial; Virbac, Carros, France) and 10 mg/kg xylazine (Rompun; Bayer Korea, Ansan, Korea) and sacrificed by decapitation. The animals underwent cardiac perfusion with phosphate-buffered saline (PBS: Dulbecco’s formula modified, ICN Biochemicals, England) before tissue harvest. The temporal bones were dissected, and the bony shells of the cochlea and vestibule were removed in chloride-free physiological saline. The animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Yonsei University, Korea (YWC-150728-1, YWC-160826-1).
2.2. Ototoxic Drug Administration
The first injection for each mouse was given at the beginning of the daily light cycle. The three subgroups ( for each group) in the ototoxicity group received subcutaneous injection of kanamycin (420, 550, and 600 mg/kg; Sigma-Aldrich Oakville, ON, Canada) dissolved in PBS, followed by an intraperitoneal injection of furosemide (130 mg/kg; Sigma-Aldrich, Oakville, ON, Canada) via the tail vein after 30 min . The mice in the sham control group received a subcutaneous injection of saline, followed by another tail vein injection of saline 30 min later. Mice showing signs of severe dehydration or other significant illness were sacrificed. All animals were monitored by trained animal care technologists supervised by a veterinarian. All animals survived the drug administration (Figure 1).
2.3. Testing of Hearing Ability
Pretest auditory brainstem response (ABR) thresholds were measured in the 24 mice (6 mice/each group) 24 h prior to the first drug administration. Each animal was gently anaesthetized with an intraperitoneal injection of ketamine (100 mg/kg; Yuhan Corporation, Seoul, Korea) and xylazine (1 mg/kg; Rompun, Korea Bayer, Ansan, Korea) and kept warm using a heating pad. Subdermal needle electrodes were placed at the scalp vertex (inverting), posterior bulla (noninverting), and lower back (ground) for recording ABR in anaesthetized mice. The test stimuli were clicks generated using the BioSigRP (Tucker-Davis Technologies, Inc.). The stimulus intensity decreased gradually in 5-dB (decibel) steps until a visually discernible ABR waveform disappeared, and the lowest sound level that caused this waveform was defined as the “threshold.” Scanning time was 10 ms, and 1024 sweeps were averaged with 300–3000 Hz filtering band-width. Threshold shifts are reported as the difference between the pre- and posttest ABR thresholds. Posttest ABR thresholds after kanamycin and furosemide administration were measured at 3, 5, 7, 10, and 14 days without any scarification to observe the changes of hearing threshold after the ototoxicity drugs.
2.4. Histological Assessment and Immunohistochemistry
Normal and ototoxic drug-administrated mice were sacrificed after 14 days of treatment. The temporal bones were removed, and the apex of the cochlea, the round window, and the oval window were punctured. A fixative was perfused on right side cochleas of three animals in each group through the cochlear apex with 4% paraformaldehyde (Biosesang, Seongnam, Korea), and the sample was immersed in fixative for 24 h at 4°C. Cochleas were decalcified by immersion in Calci-Clear Rapid (National Diagnostics, Atlanta, GA, USA) for 24 h, dehydrated in 30% sucrose (Sigma-Aldrich, Gillingham, UK) for 24 h, embedded in the optimal cutting temperature (OCT) compound (Leica, Bensheim, Germany), and sectioned from 2 to 10 μm thickness using a cryostat (Leica CM1850 Cryostat; Leica, Wetzlar, German). A standard hematoxylin and eosin (H & E) staining protocol was followed, with a 1–3 min incubation in hematoxylin and 30–60 s staining with eosin, before mounting the samples.
Immunohistochemistry for SDF-1 was performed on the cryosections of the cochlea in each group. The slide samples were incubated with appropriate primary antibodies as follows. Antibody against SDF-1 1 (Abcam, Inc., Cat #ab18919) was used. Sections were incubated with the primary antibody overnight at 4°C. After washing thrice with 0.1 M PBS, the sections were incubated with an appropriate biotin-tagged secondary antibody at room temperature for 1 h. Thereafter, the sections were incubated in an avidin-biotin-peroxidase complex solution (Vector Laboratories, Inc., Burlingame, CA, USA) and developed with diaminobenzidine substrate kit (Vector Laboratories, Inc.) after washing thrice with 0.1 M PBS. Then, the sections were dehydrated, mounted, and visualized with a BX50 microscope (Olympus, Tokyo, Japan), and digital images were captured.
2.5. Immunofluorescent Microscopy
The temporal bones of the left side in three mice of each group that were sacrificed for the histology were fixed and decalcified as described above. Subsequently, the basilar membrane was dissected under a dissecting microscope, and the stria vascularis and the tectorial membrane were removed. To identify -actin and cell nucleus in the sensory epithelium, phalloidin-FITC (Sigma-Aldrich, Chemie BV, Zwijndrecht, the Netherlands) was applied for 40 min at room temperature in a dark room. The fluorescent signals were visualized using a BX50 microscope (Olympus, Tokyo, Japan) and digital images were captured. The outer hair cells in the sensory epithelium were counted from a minimum of 10 captures per cochlea, including the apical, mid, and basal turns.
2.6. Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analysis
Total RNA was isolated with the TRIzol Reagent (Invitrogen, Carlsbad, CA) from the sensory epithelium of right cochlea of three mice in each group, which were sacrificed 3, 5, 7, and 14 days after the treatment. On day 0 before the ototoxicity, the results were replaced by those from the control group (). Total RNA was subjected to reverse transcription using the SYBR® Select master mix (Applied Biosystems, CA, USA) following the manufacturer’s protocol. Real-time RT-PCR was performed using Applied Biosystems sequence detection system 7900 to quantify SDF-1 levels. The following primers were used for sequencing: SDF-1, forward: 5′-CGC CAG AGC CAA CGT CAA GC-3′ and reverse: 5′-TTT GGG TCA ATG CAC ACT TG-3′; β-actin, forward: 5′-CGT GCG TGA CAT CCA AGA GAA-3′ and reverse: 5′-TGG ATG CCA CAG GAT TCC AT-3′. To exclude the possibility of genomic DNA amplification during PCR, no-template controls were performed and accepted when the Ct value was at least nine cycles greater than the template run. Measurements were performed in duplicate and accepted if the difference in Ct values between the duplicates was less than 1. The real-time PCR data were normalized to the level of β-actin, and the relative quantity of mRNA was determined using the comparative cycle threshold method.
2.7. Statistical Analysis
Statistical analysis was performed using the SPSS statistical package version 17.0 (SPSS, Chicago, IL, USA). Descriptive results of continuous variables are expressed as mean ± standard deviation (SD) for normal distribution variables. Means were compared by the 2-way analysis of variance (ANOVA) for ABR tests and Mann–Whitney test for counts of hair cells and SDF-1. The level of statistical significance was set at 0.05.
3.1. Changes in the Hearing Thresholds of the Kanamycin/Furosemide-Induced Mouse Model of Ototoxicity
ABR evaluations were performed at 0, 3, 5, 7, 10, and 14 days after drug administration to test whether the combined effect of kanamycin/furosemide is able to induce hearing loss in mice. We compared the average ABR thresholds for the four groups, which was measured with click sounds (Figure 2(a)). The ABR thresholds were significantly elevated in the groups receiving both drugs, namely, furosemide 130 mg/kg + kanamycin 420 mg/kg, furosemide 130 mg/kg + kanamycin 550 mg/kg, and furosemide 130 mg/kg + kanamycin 600 mg/kg, compared to that of the control group at each frequency (). Abrupt changes in threshold in the ototoxicity groups occurred after 3 days of drug administration. High doses of kanamycin caused more severe hearing impairment in the third to the fourteenth day posttreatment, as seen by an increase in the ABR threshold in the furosemide 130 mg/kg + kanamycin 600 mg/kg group than in the furosemide 130 mg/kg + kanamycin 420 and 550 mg/kg groups. Final hearing levels worsened with administration of different concentrations of kanamycin; however, there were no significant differences among them. Despite definite changes in the hearing threshold, the body weights of mice treated with kanamycin 600 mg/kg decreased, and 4 among 15 mice died of urinary insufficiency within 7 days (Figure 2(b)). However, no such problem occurred in mice treated with the other doses of kanamycin.
3.2. Cochlear Histopathology of Kanamycin/Furosemide-Treated Mice
To examine the ototoxic effects of furosemide and kanamycin, structural changes in the inner ear were examined by H & E staining of cochlear sections 14 days after the drug administration. We observed a loss of inner and outer hair cells in mice treated with a combination of kanamycin and furosemide, which caused damage of the organ of Corti (Figure 3). The loss of outer hair cells in the organ of Corti was higher in the cochlea exposed to kanamycin/furosemide than in the normal cochlea. At the same time, there was a reduction in the number of spiral ganglia cells and thinning of the stria vascularis in the groups receiving both the drugs. High doses of kanamycin (550 and 600 mg/kg) caused more severe structural changes.
3.3. Hair Cell Counts in Kanamycin/Furosemide-Treated Mice
The process of degeneration in the organ of Corti 14 days after drug administration was examined by the structure analysis using immunofluorescence microscopy (Figure 4). Cochleas from furosemide 130 mg/kg + kanamycin 550 mg/kg and furosemide 130 mg/kg + kanamycin 600 mg/kg treated mice were analyzed. The alignment of outer hair cells (OHCs), indicated by their V-shaped bundles, indicated that the organization of the organ of Corti and the stereocilia bundle integrity were well-maintained at this stage. In contrast, damage to the stereocilia was observed in the furosemide 130 mg/kg + kanamycin 550 mg/kg treated mice, which was more evident in mice treated with furosemide 130 mg/kg + kanamycin 600 mg/kg, particularly at the top of their V-shaped bundles. In addition, the hair cells presented an increasingly disorderly rearrangement, and some OHC stereocilia and the cuticular plate were absent. To quantify bundle damage caused by furosemide and kanamycin sulfate, the total number of bundles of the three-layered outer hair cells was counted. Combined injection of furosemide and kanamycin sulfate caused a significant reduction in the number of bundles of the inner and outer hair cells in the furosemide 130 mg/kg + kanamycin 550 mg/kg and furosemide 130 mg/kg + kanamycin 600 mg/kg groups compared to that of the control group ().
3.4. Changes in SDF-1 Level in the Kanamycin/Furosemide-Treated Mice
SDF-1 is an important chemokine required for the homing of mesenchyme-derived stem cells. We observed that the mRNA levels of SDF-1 increased with concentration of kanamycin (Figure 5), reaching maxima in the furosemide 130 mg/kg + kanamycin 550 mg/kg group. However, the levels decreased in the furosemide 130 mg/kg + kanamycin 600 mg/kg group. Next, we measured the change in SDF-1 with time using 550 mg/kg kanamycin. The hearing thresholds dropped suddenly on the third day. In contrast, the mRNA levels of SDF-1 were highest on the 7th day and decreased afterwards. Next, we investigated the extent and timing of the increase in the protein levels of SDF-1 (Figure 6). SDF-1 was detected in the stria vascularis, Reissner’s membrane, organ of Corti, and the spinal ganglion, confirming that SDF-1 was expressed mostly in the damaged area as ototoxicity progressed in the second week. Furthermore, the stria vascularis and organ of Corti showed the highest increase in expression. Both outer and inner hair cells also showed increased expression.
Stem cell homing via circulation to the bone marrow is the first critical step in regenerative medicine [6, 7]. Stem cell homing is one of the crucial mechanisms that has to be activated for efficient cell delivery to the inner ear . Sensory hair cells of the inner ear are responsible for conducting auditory stimulation. The hair cells in the inner ear are never replaced and are regenerated after injury. Injection of neural stem cells for homing to the injured cochlea is required to induce regeneration via the supporting cells in the organ of Corti following inner ear trauma . However, there are only few animal models for an increasing number of homing factors, showing an obvious dearth of appropriate study models. Tan et al.  studied the homing capability of bone marrow-derived stem cells to the deafened cochlea in the rat model 3 months after acoustic deafening. Here, we attempted to develop a mouse model with an optimal increase of SDF-1 for homing studies. This would be a useful tool to evaluate the efficacy of stem cell therapy for other related researchers.
SDF-1 (CXCL12), a member of the C-X-C family of chemokines, plays an important role in cell migration at the injured site . CXCR4 on the circulating stem cells are trapped by SDF-1, which represent high-affinity cell surface integrins. In the presence of the SDF-1-CXCR4 combination, the cells stop rolling, disseminate, and migrate through the vascular endothelium towards the chemokine gradient [10, 11]. Kamiya  transplanted MSCs in the cochlea after the induction of SDF-1 in CX26-deficient mice, which was used as a model of hereditary hearing loss . We observed optimal induction of the stem cell homing factor in the newly generated aminoglycoside-induced ototoxicity mouse model using a “one-shot” protocol. There was a significant reduction in hearing thresholds and a maximal increase of SDF-1 levels when furosemide 130 mg/kg + kanamycin 550 mg/kg was used to treat the mice. Severe ototoxicity was observed in the furosemide 130 mg/kg + kanamycin 600 mg/kg group, which was accompanied by distorted structures in the organ of Corti, cell death, and weight loss among the population with urinary insufficiency. Since high doses of aminoglycoside cause drug-induced nephrotoxicity [13, 14], the nephrotoxicity induced by kanamycin 600 mg/kg, which manifested as a reduction in urine volume, was considered as a case of renal failure. There were no such symptoms in the other groups, which were treated with doses of kanamycin less than 550 mg/kg. The hearing thresholds decreased abruptly on the 3rd day and plateaued on the 5th day after the ototoxicity injury. We consider the 7th day posttreatment as the optimal day for the homing mouse model with aminoglycoside ototoxicity, because SDF-1 levels peaked on the 7th day after the drug treatment.
Immunohistochemistry performed on the 7th day posttreatment showed that SDF-1 was distributed diffusely in the stria vascularis, Reissner’s membrane, organ of Corti, and spinal ganglion. This observation corroborates the results obtained with kanamycin-mediated injury. Extensive destruction of the outer hair cells in the triple-layer arrays and decreased count and vacuolization of the spiral ganglion cells were typical initial characteristics of cochlea exposed to ototoxicity . However, dominant staining with the SDF-1 antibody in the scala vascularis represented the possibility of increasing the homing effect of the stem cells, because scala vascularis consists of condensed vascular structures.
The “one-shot” injection with combinations of kanamycin and furosemide in the mouse model of ototoxicity is a novel technique for inducing local inner ear injury [16–18]. Abbas and Rivolta  showed the efficiency of the “one-shot” approach. A single dose regimen might be a reliable model for ototoxicity-mediated hearing loss with kanamycin and adequate for inducing rapid and profound hearing impairment. Furthermore, it reduces the risks associated with chronic treatment of aminoglycoside and is thus preferred for animal welfare. Although Abbas et al.  used 400–500 mg/kg kanamycin, followed by an intraperitoneal injection of furosemide 100 mg/kg after 20–30 mins in gerbils, we used various doses of kanamycin (420–600 mg/kg) with 130 mg/kg furosemide in C57BL/6 mice. We observed that ototoxicity-mediated hearing impairment occurred upon using kanamycin doses equal to or greater than 420 mg/kg. However, we conclude that the optimal dose of kanamycin for the homing mice model of ototoxicity is 550 mg/kg. In the future, we will use this animal model to study the MSC homing in the ototoxicity mice after the injection of MSCs intratympanically or intravenously, which have increased potency of CXCR4 with hypoxic conditions.
Investigation regarding the mechanism of ototoxicity induced by the combination of kanamycin-furosemide is important for understanding stem cell homing in the inner ear [19–21]. In future, we would use the SDF-1/CXCR4 axis to induce MSC homing in the injured cochlear site in this mice model through the administration of MSC with elevated CXCR4 expression. Eventually, studies regarding high SDF-1 levels in our mouse model of ototoxicity would play a major role in the development of therapeutic agents using MSC homing.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1A6A3A11933471), by the Gangwon Institute for Regional Program Evaluation grant funded by the Korean government (Ministry of Trade, Industry and Energy) (no. R0005797), and by Industrial Core Technology Development Program of Biomedical Devices funded by the Ministry of Trade, industry and Energy (MI, Korea) (10051518).
- L. Abbas and M. N. Rivolta, “Aminoglycoside ototoxicity and hair cell ablation in the adult gerbil: A simple model to study hair cell loss and regeneration,” Hearing Research, vol. 325, pp. 12–26, 2015.
- S. Murillo-Cuesta, J. Contreras, R. Cediel, and I. Varela-Nieto, “Comparison of different aminoglycoside antibiotic treatments to refine ototoxicity studies in adult mice,” Laboratory Animals, vol. 44, no. 2, pp. 124–131, 2010.
- B. T. G. Tan, M. M. G. Lee, and R. Ruan, “Bone marrow-derived cells that home to acoustic deafened cochlea preserved their hematopoietic identity,” Journal of Comparative Neurology, vol. 509, no. 2, pp. 167–179, 2008.
- K. Kamiya, “Inner ear cell therapy targeting hereditary deafness by activation of stem cell homing factors,” Frontiers in Pharmacology, vol. 6, article no. 02, 2015.
- H. M. Schmitz, S. B. Johnson, and P. A. Santi, “Kanamycin-furosemide ototoxicity in the mouse cochlea: A 3-dimensional analysis,” Otolaryngology - Head and Neck Surgery (United States), vol. 150, no. 4, pp. 666–672, 2014.
- J. P. Chute, “Stem cell homing,” Current Opinion in Hematology, vol. 13, no. 6, pp. 399–406, 2006.
- F. Belema-Bedada, S. Uchida, A. Martire, S. Kostin, and T. Braun, “Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2,” Cell Stem Cell, vol. 2, no. 6, pp. 566–575, 2008.
- T. Okano and M. W. Kelley, “Stem Cell Therapy for the Inner Ear: Recent Advances and Future Directions,” Trends in Hearing, vol. 16, no. 1, pp. 4–18, 2012.
- C. Yellowley, “CXCL12/CXCR4 signaling and other recruitment and homing pathways in fracture repair,” BoneKEy Reports, vol. 2, no. 3, 2013.
- P. Kolar, K. Schmidt-Bleek, H. Schell et al., “The early fracture hematoma and its potential role in fracture healing,” Tissue Engineering—Part B: Reviews, vol. 16, no. 4, pp. 427–434, 2010.
- J. M. Fox, G. Chamberlain, B. A. Ashton, and J. Middleton, “Recent advances into the understanding of mesenchymal stem cell trafficking,” British Journal of Haematology, vol. 137, no. 6, pp. 491–502, 2007.
- K. Kamiya, S. W. Yum, N. Kurebayashi et al., “Assembly of the cochlear gap junction macromolecular complex requires connexin 26,” The Journal of Clinical Investigation, vol. 124, no. 4, pp. 1598–1607, 2014.
- F. Van Bambeke, P. M. Tulkens, R. Brasseur, and M.-P. Mingeot-Leclercq, “Aminoglycoside antibiotics induce aggregation but not fusion of negatively-charged liposomes,” European Journal of Pharmacology: Molecular Pharmacology, vol. 289, no. 2, pp. 321–333, 1995.
- Pharmacologic the Chinchilla1, 1. 2005:1-6.
- P. A. Leake, A. L. Kuntz, C. M. Moore, and P. L. Chambers, “Cochlear pathology induced by amimoglycoside ototoxicity during postnatal maturation in cats,” Hearing Research, vol. 113, no. 1-2, pp. 117–132, 1997.
- T. Nakagawa, T. S. Kim, N. Murai et al., “A novel technique for inducing local inner ear damage,” Hearing Research, vol. 176, no. 1-2, pp. 122–127, 2003.
- Y. Quan, L. Xia, J. Shao et al., “Adjudin protects rodent cochlear hair cells against gentamicin ototoxicity via the SIRT3-ROS pathway,” Scientific Reports, vol. 5, p. 8181, 2015.
- Q. Ruan, H. Ao, J. He et al., “Topographic and quantitative evaluation of gentamicin-induced damage to peripheral innervation of mouse cochleae,” NeuroToxicology, vol. 40, pp. 86–96, 2014.
- K. Kamiya, Y. Fujinami, N. Hoya et al., “Mesenchymal stem cell transplantation accelerates hearing recovery through the repair of injured cochlear fibrocytes,” The American Journal of Pathology, vol. 171, no. 1, pp. 214–226, 2007.
- H. M. Ju, S. H. Lee, T. H. Kong, S. Kwon, J. S. Choi, and Y. J. Seo, “Usefulness of intravital multiphoton microscopy in visualizing study of mouse cochlea and volume changes in the scala media,” Frontiers in Neurology, vol. 8, 2017.
- J. S. Hwang, K. H. Kim, and J. H. Lee, “Factors affecting sentence-in-noise recognition for normal hearing listeners and listeners with hearing loss,” Journal of Audiology and Otology, vol. 21, no. 2, pp. 81–87, 2017.
Copyright © 2017 Hyun Mi Ju et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.